$1.4 million SBIR grant fast-tracks antibody technology for pharmaceutical manufacturers

(Purdue University) Novilytic LLC, a company that secures lifesaving drugs and medical devices and is based in the Purdue Research Park West Lafayette, has been awarded a Phase II SBIR contract by the National Institute of General Medical Sciences, one of the National Institutes of Health. The $1.4 million Phase II contract will allow Novilytic to continue the research, development and commercialization of its new instrument for process chemists and engineers who need to develop better process quality and control.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news